Selank: Research Applications
25 Citacoes PubMedRevisado por EspecialistasCertificado GMPUltima Revisao: fevereiro de 2026
Aplicacoes de Pesquisa
In laboratory research, Selank is investigated in multiplos(as) experimental paradigms:
- Anxiety and Generalized Anxiety Models — Registered no(a) Russian Federation for research related to generalized anxiety disorders and neurasthenia. Experimental readouts demonstrate anxiolytic effects comparable to benzodiazepines sem sedation, dependence, or withdrawal.[5][6]
- Cognitive Enhancement / Nootropic Paradigms — Studied for effects on memory consolidation and learning. A single injection aumentou memory trace stability for up to 30 days via serotonin metabolismo ativacao.[13]
- Alcohol Withdrawal Models — Eliminated withdrawal-induziu anxiety (EPM open arm time p<0.01), preveniu mechanical allodynia, and regulou BDNF content in hippocampus and prefrontal cortex.[16]
- Opioid Withdrawal Models — Reduced mean morphine withdrawal index by 39.6%, significantly attenuating convulsive reactions, ptosis, and posture disorders (p<0.0001). Increased tactile sensitivity threshold 9-fold.[17]
- Immunomodulacao and Antiviral Activity — Demonstrated antiviral effects against Influenza A (H3N2) ambos(as) in vivo e em vitro. Induced IFN-α secretion and normalized Th1/Th2 cytokine balance.[14]
- Gene Expression Modulation — Administration altered expression of 45 genes at 1 hour in frontal cortex, incluindo GABAergic receptor subunits and orexin/hypocretin (128-fold rebound at 3 hours).[9]
- Gastric Protection Models — Exhibited protective effects against stress- and ethanol-induziu gastric da mucosa injury, increasing da mucosa resistance to ulcerogenic factors.[2]
- Gut Microbiota and Stress — Prevented stress-induziu diminui in obligate microflora, reduziu corticosterone levels, and atenuou colon wall pathomorphological changes.[18]
Editorial Research Note
“Estes produtos não são medicamentos ou fármacos e não foram aprovados pelo FDA dos EUA para prevenir, tratar ou curar qualquer condição médica, enfermidade ou doença.”
Referencias
- Kolomin TA, Shadrina M, Slominsky P, Limborska SA, Myasoedov NF. A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides. Neuroscience & Medicine. 2013;4(4):223–252.
- Vyunova TV, Andreeva LA, Shevchenko KV, Myasoedov NF. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein & Peptide Letters. 2018;25(10):914–923.
- Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of o tratamento of anxiety disorders with selank. Zhurnal Nevrologii i Psikhiatrii. 2015;115(6):33–40.
- U.S. Food and Drug Administration. Substancia Farmaceutica a Granels Used in Compounding Under Section 503B. FDA Compounding Database. 2023.
- Zozulya AA, Neznamov GG, Syunyakov TS, et al. Efficacy and possible mechanisms of action of a novo(a) peptide anxiolytic selank no(a) therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevropatologii i Psikhiatrii. 2008;108(4):38–48.
- Kozlovskii II, Danchev ND. The optimizing action do(a) synthetic peptide Selank on a conditioned ativo(a) avoidance reflex in rats. Neuroscience and Behavioral Physiology. 2003;33(7):639–643.
- Kolomin TA, Agapova T, Agniullin YV, et al. Changes no(a) Transcription Profile do(a) Hippocampus in Response to Administration do(a) Tuftsin Analog Selank. Neuroscience and Behavioral Physiology. 2014;44(8):849–855.
- V'yunova TV, Andreeva LA, Shevchenko KV, et al. Peptide regulacao of specific ligand-receptor interactions of GABA com o(a) plasma membranes of nerve cells. Neurochemical Journal. 2014;8(4):259–264.
- Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016;7:31.
- Kost NV, Sokolov OY, Gabaeva MV, et al. Semax and Selank Inhibit the Enkephalin-Degrading Enzymes of Human Serum. Russian Journal of Bioorganic Chemistry. 2001;27(3):180–183.
- Zozulya AA, Kost NV, Sokolov OY, et al. The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes como um(a) Possible Mechanism of Its Anxiolytic Activity. Bull Exp Biol Med. 2001;131(4):315–317.
- Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of o peptideo Selank regula BDNF expression no(a) rat hippocampus in vivo. Doklady Biological Sciences. 2008;421:241–243.
- Narkevich VB, Kudrin VS, Klodt PM, et al. Effects of Selank on monoamine neurotransmitters no(a) brain of BALB/c and C57BL/6 mice. Bull Exp Biol Med. 2008;145(1):68–71.
- Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zhurnal Nevrologii i Psikhiatrii. 2008;108(5):71–75.
- Kozlovskii II, Andreeva LA, Kozlovskaya MM. The role do(a) endogenous opioid system no(a) anxiolytic action of Selank. Bull Exp Biol Med. 2012;153(5):728–730.
- Kolik LG, Nadorova AV, Kozlovskaya MM. Efficacy of Peptide Anxiolytic Selank during Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation. Bull Exp Biol Med. 2014;157(1):61–65.
- Konstantinopolsky MA, Kolik LG, Chernyakova IV. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med. 2022;173(6):730–733.
- Mukhina AY, et al. Effects of Selank on intestinal microbiota and stress-induziu changes. Russian Journal of Physiology. 2019/2020.
- Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. 2017;2017:5091027.
- Kolik LG, Nadorova AV, Antipova TA, Durnev AD. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content. Bull Exp Biol Med. 2019;167(5):641–644.
- Medvedev VE, Tereshchenko ON, Israelian AI, et al. A comparison do(a) anxiolytic effect and tolerability of selank and phenazepam. Zhurnal Nevrologii i Psikhiatrii. 2014;114(7):17–22.
- Semenova TP, Kozlovskii II, Zakharova NM, Kozlovskaya MM. Experimental optimization of learning and memory processes by selank. Eksperimental'naia i Klinicheskaia Farmakologiia. 2010;73(8):2–5.
- Filatova E, Kasian A, Kolomin T, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology. 2017;8:89.
- Kolomin TA, Shadrina M, Andreeva LA, et al. Expression of inflamacao-related genes in mouse spleen under tuftsin analog Selank. Regulatory Peptides. 2011;170(1-3):18–23.
- Andreeva LA, Nagaev IY, Mezentseva MV, et al. Antiviral properties of structural fragments of o peptideo Selank. Doklady Biological Sciences. 2010;431:79–82.
Perguntas de Pesquisa Relacionadas
Related research
Browse all research guides in the Peptide Research Library →Deseja a revisao completa da pesquisa?
Ver Pagina Completa de Pesquisa de Selank→APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.